RhumbLine Advisers
ACRV icon

RhumbLine Advisers’s Acrivon Therapeutics ACRV Stock Holding History

RhumbLine Advisers’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,600
Closed -$33.7K – 4141
2025
Q1 		$33.7K Sell
16,600
-1,155
-7% -$6.22K ﹤0.01% 3655
2024
Q4 		$107K Sell
17,755
-5
-0% -$36 ﹤0.01% 3460
2024
Q3 		$124K Buy
17,760
+1,551
+10% +$12.2K ﹤0.01% 3442
2024
Q2 		$94K Buy
16,209
+5,320
+49% +$42.8K ﹤0.01% 3530
2024
Q1 		$77.8K Buy
10,889
+1,619
+17% +$7.51K ﹤0.01% 3521
2023
Q4 		$45.6K Sell
9,270
-207
-2% -$1.09K ﹤0.01% 3647
2023
Q3 		$90.6K Buy
9,477
+491
+5% +$5.67K ﹤0.01% 3495
2023
Q2 		$116K Buy
+8,986
New +$109K ﹤0.01% 3460

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

RhumbLine Advisers's ACRV Position: Q2 2025 in Review

RhumbLine Advisers sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 16,600 shares — an estimated $33.7K sold.

RhumbLine Advisers first reported a position in ACRV in Q2 2023 and held it in 8 quarters. The position peaked at $124K in Q3 2024. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • RhumbLine Advisers reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 16,600 Acrivon Therapeutics shares in Q2 2025, an estimated $33.7K.
  • RhumbLine Advisers first reported a position in Acrivon Therapeutics in Q2 2023 and held it in 8 quarters.
  • RhumbLine Advisers's Acrivon Therapeutics position peaked at $124K in Q3 2024.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.